{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T05:07:29Z","timestamp":1773637649817,"version":"3.50.1"},"reference-count":175,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RAIAD"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Psoriasis (PsR), a chronic autoimmune disorder, affects millions of individuals globally\nand has a substantial impact on their quality of life. This complex condition involves intricate\nmolecular networks and signaling pathways, making the development of effective treatments\na significant challenge. Moreover, to advance treatment options, precise targeting of cells\nthrough the identification of protein biomarkers in PsR has emerged as a promising field of research\nfor both fundamental and clinical scientists. These protein components provide valuable\ninsights into the underlying mechanisms of the disease and can serve as indicators of treatment\nresponse. Furthermore, by identifying specific biocomponents, researchers can develop targeted\ntherapeutics that address the molecular abnormalities driving PsR. The use of biologics as potential\ntargets for improving treatment efficacy is a significant focus in PsR research. Biologics,\nwhich include monoclonal antibodies and fusion proteins, specifically target key molecules involved\nin the immune response, such as tumor necrosis factor-alpha (TNF-\u03b1) and interleukins\n(IL). These targeted therapies have demonstrated substantial efficacy in managing PsR by modulating\nthe immune system and reducing inflammation. Recent advancements in moleculartargeted\ntherapies utilizing biologics or small-molecule inhibitors have contributed to improving\npatient outcomes. This review aims to summarize the recent discoveries and insights regarding\nbiocomponents and their importance in treating PsR, encompassing both its inflammatory and\ndermatological aspects. Furthermore, the review discusses the commercial outcomes of ongoing\nclinical trials for various biological-based therapeutic modalities for PsR, providing valuable\ninsights into the evolving landscape of PsR therapeutics. These developments indicate the growing\ninterest and investment in improving treatment options for individuals living with PsR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0127722708331606250128063129","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T05:15:56Z","timestamp":1739337356000},"page":"47-75","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Insights into Protein-based Therapies for Precision Targeting of Psoriasis"],"prefix":"10.2174","volume":"20","author":[{"given":"Krishna","family":"Yadav","sequence":"first","affiliation":[{"name":"Rungta College of Pharmaceutical Sciences and Research, Kohka, Bhilai, Chhattisgarh, 490024, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Vijayalakshmi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, GIET School of Pharmacy, Chaitanya Knowledge City, Rajahmundry, AP, 533296, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kantrol Kumar","family":"Sahu","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, 281406, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Sucheta","sequence":"additional","affiliation":[{"name":"School of Medical and Allied Sciences, K.R. Mangalam University, Sohna Road, Gurugram, Haryana, 122103, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kushagra","family":"Nagori","sequence":"additional","affiliation":[{"name":"Rungta College of Pharmaceutical Sciences and Research, Kohka, Bhilai, Chhattisgarh, 490024, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deependra","family":"Singh","sequence":"additional","affiliation":[{"name":"University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, 492010, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju Rawat","family":"Singh","sequence":"additional","affiliation":[{"name":"University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, 492010, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhulika","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Gracious College of Pharmacy,Abhanpur, Chhattisgarh, 493661, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"109945","DOI":"10.1016\/j.intimp.2023.109945","volume":"117","author":"Yadav K.","year":"2023","unstructured":"Yadav K.; Singh D.; Singh M.R.; Preclinical study models of psoriasis: State-of-the-art techniques for testing pharmaceutical products in animal and nonanimal models. Int Immunopharmacol  2023,117,109945","journal-title":"Int Immunopharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"110322","DOI":"10.1016\/j.mehy.2020.110322","volume":"145","author":"Yadav K.","year":"2020","unstructured":"Yadav K.; Singh D.; Singh M.R.; Pradhan M.; Multifaceted targeting of cationic liposomes via co-delivery of anti-il-17 sirna and corticosteroid for topical treatment of psoriasis. Med Hypotheses  2020,145,110322","journal-title":"Med Hypotheses"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"102168","DOI":"10.1016\/j.jddst.2020.102168","volume":"61","author":"Pradhan M.","year":"2021","unstructured":"Pradhan M.; Alexander A.; Singh M.R.; Statistically optimized calcipotriol fused nanostructured lipid carriers for effectual topical treatment of psoriasis. J Drug Deliv Sci Technol  2021,61,102168","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=4","author":"Rawat Singh M","year":"2021","unstructured":"Rawat Singh M; Singh D; Sahu KK; Pradhan M; Yadav K; A method of preparation of Triamcinolone Acetonide encapsulated nanostructured lipid carriers for psoriasis treatment.  2021"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2174\/1871526520666200622142710","volume":"21","author":"Ahuja A.","year":"2021","unstructured":"Ahuja A.; Gupta J.; Gupta R.; Miracles of herbal phytomedicines in treatment of skin disorders: Natural healthcare perspective. Infect Disord Drug Targets  2021,21(3),328-338","journal-title":"Infect Disord Drug Targets"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/B978-0-323-42868-2.00011-5","volume":"1","author":"Singh D","year":"2016","unstructured":"Singh D; Pradhan M; Shrivastava S; Murthy SN; Singh MR; Skin autoimmune disorders: Lipid biopolymers and colloidal delivery systems for topical delivery Nanobiomat Galen Formulat Cosmet  2016,1(1),257-96","journal-title":"Nanobiomat Galen Formulat Cosmet"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1341708","DOI":"10.3389\/fimmu.2023.1341708","volume":"14","author":"Gargiulo L.","year":"2024","unstructured":"Gargiulo L.; Ibba L.; Malagoli P.; Drug survival of il-12\/23, il-17 and il-23 inhibitors for moderate-to-severe plaque psoriasis: A retrospective multicenter real-world experience on 5932 treatment courses \u2013 il pso (italian landscape psoriasis). Front Immunol  2024,14,1341708","journal-title":"Front Immunol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/B978-0-323-95303-0.00013-7","author":"Mongia P.R.","year":"2024","unstructured":"Mongia P.R.; Amrita M.S.; Sahu K.; Chapter 5 - Multifunctional nanocarrier-mediated delivery for targeting and treating skin cancer. In: Yadav AK, Shukla R, Ujjwal RR, Eds. Multifunct Nanocomposites Target Drug Deliv Cancer Ther  2024,113-138","journal-title":"Multifunct Nanocomposites Target Drug Deliv Cancer Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/ijms18112297","volume":"18","author":"R\u00f8nholt K.","year":"2017","unstructured":"R\u00f8nholt K.; Iversen L.; Old and new biological therapies for psoriasis. Int J Mol Sci  2017,18(11),2297","journal-title":"Int J Mol Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.medidd.2024.100183","volume":"22","author":"Yadav K.","year":"2024","unstructured":"Yadav K.; Kumar Sahu K.; Sucheta R.; A complex molecular landscape to drug delivery concept for achieving precise therapy in psoriasis. Med Drug Discov  2024,22(2024),1-23","journal-title":"Med Drug Discov"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jddst.2017.07.024","volume":"41","author":"Pradhan M.","year":"2017","unstructured":"Pradhan M.; Singh D.; Singh M.R.; Fabrication, optimization and characterization of triamcinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis: Application of box behnken design, in vitro and ex vivo studies. J Drug Deliv Sci Technol  2017,41,325-333","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1078\/0171-9335-00401","volume":"83","author":"Herzog V.","year":"2004","unstructured":"Herzog V.; Kirfel G.; Siemes C.; Schmitz A.; Biological roles of app in the epidermis. Eur J Cell Biol  2004,83(11-12),613-624","journal-title":"Eur J Cell Biol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3109\/08916930903510906","volume":"43","author":"Albanesi C.","year":"2010","unstructured":"Albanesi C.; Scarponi C.; Bosisio D.; Sozzani S.; Girolomoni G.; Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity  2010,43(3),215-219","journal-title":"Autoimmunity"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/bjd.12049","volume":"168","author":"Hald A.","year":"2013","unstructured":"Hald A.; Andr\u00e9s R.M.; Salskov-Iversen M.L.; Kjellerup R.B.; Iversen L.; Johansen C.; Stat1 expression and activation is increased in lesional psoriatic skin. Br J Dermatol  2013,168(2),302-310","journal-title":"Br J Dermatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1951291","DOI":"10.1080\/15321819.2021.1951291","volume":"43","author":"Pradhan M.","year":"2022","unstructured":"Pradhan M.; Shah K.; Alexander A.; Covid-19: Clinical presentation and detection methods. J Immunoassay Immunochem  2022,43(1),1951291","journal-title":"J Immunoassay Immunochem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"104152","DOI":"10.1016\/j.jddst.2023.104152","volume":"80","author":"Sahu K.K.","year":"2023","unstructured":"Sahu K.K.; Pradhan M.; Singh D.; Singh M.R.; Yadav K.; Non-viral nucleic acid delivery approach: A boon for state-of-the-art gene delivery. J Drug Deliv Sci Technol  2023,80,104152","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-3-031-63677-6_10","author":"Yadav K.","year":"2024","unstructured":"Yadav K.; Sucheta R.; Vijayalakshmi R.; Phyto-nanomedicine for the treatment of autoimmune and other related skin disorders. Med Appl Phytopharm  2024,159-190","journal-title":"Med Appl Phytopharm"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3390\/biomedicines11020613","volume":"11","author":"Singh S.K.","year":"2023","unstructured":"Singh S.K.; Dwivedi S.D.; Yadav K.; Novel biotherapeutics targeting biomolecular and cellular approaches in diabetic wound healing. Biomedicines  2023,11(2),613","journal-title":"Biomedicines"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jconrel.2013.05.020","volume":"170","author":"Pradhan M.","year":"2013","unstructured":"Pradhan M.; Singh D.; Singh M.R.; Novel colloidal carriers for psoriasis: Current issues, mechanistic insight and novel delivery approaches. J Control Release  2013,170(3),380-395","journal-title":"J Control Release"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jprot.2016.03.040","volume":"140","author":"Reindl J.","year":"2016","unstructured":"Reindl J.; Pesek J.; Kr\u00fcger T.; Proteomic biomarkers for psoriasis and psoriasis arthritis. J Proteomics  2016,140,55-61","journal-title":"J Proteomics"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.gpb.2015.04.002","volume":"13","author":"Jiang S.","year":"2015","unstructured":"Jiang S.; Hinchliffe T.E.; Wu T.; Biomarkers of an autoimmune skin disease\u2014psoriasis. Genomics Proteomics Bioinformatics  2015,13(4),224-233","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"13330","DOI":"10.3390\/ijms232113330","volume":"23","author":"Purzycka-Bohdan D.","year":"2022","unstructured":"Purzycka-Bohdan D.; Nedoszytko B.; Zab\u0142otna M.; Gle\u0144 J.; Szczerkowska-Dobosz A.; Nowicki R.J.; Chemokine profile in psoriasis patients in correlation with disease severity and pruritus. Int J Mol Sci  2022,23(21),13330","journal-title":"Int J Mol Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/jid.2013.526","volume":"134","author":"Keijsers R.R.M.C.","year":"2014","unstructured":"Keijsers R.R.M.C.; Hendriks A.G.M.; van Erp P.E.J.; In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing ror\u03b3t and il-17. J Invest Dermatol  2014,134(5),1276-1284","journal-title":"J Invest Dermatol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2174\/1389201023666220309152340","volume":"23","author":"Rahman M.A.","year":"2022","unstructured":"Rahman M.A.; Abul Barkat H.; Harwansh R.K.; Deshmukh R.; Carbon-based nanomaterials: Carbon nanotubes, graphene, and fullerenes for the control of burn infections and wound healing. Curr Pharm Biotechnol  2022,23(12),1483-1496","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jconrel.2023.09.016","volume":"363","author":"Tiwari P.","year":"2023","unstructured":"Tiwari P.; Yadav K.; Shukla R.P.; Surface modification strategies in translocating nano-vesicles across different barriers and the role of bio-vesicles in improving anticancer therapy. J Control Release  2023,363,290-348","journal-title":"J Control Release"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/14740338.2020.1785427","volume":"19","author":"Wang W.M.","year":"2020","unstructured":"Wang W.M.; Jin H.Z.; Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf  2020,19(8),969-980","journal-title":"Expert Opin Drug Saf"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1208\/s12248-014-9637-0","volume":"16","author":"Wang J.","year":"2014","unstructured":"Wang J.; Wang Y.M.C.; Ahn H.Y.; Biological products for the treatment of psoriasis: Therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications. AAPS J  2014,16(5),938-947","journal-title":"AAPS J"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/1744666X.2017.1244004","volume":"13","author":"Turina M.C.","year":"2017","unstructured":"Turina M.C.; Landew\u00e9 R.; Baeten D.; Lessons to be learned from serum biomarkers in psoriasis and ibd \u2013 the potential role in spa. Expert Rev Clin Immunol  2017,13(4),333-344","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.steroids.2015.05.012","volume":"101","author":"Pradhan M.","year":"2015","unstructured":"Pradhan M.; Singh D.; Murthy S.N.; Singh M.R.; Design, characterization and skin permeating potential of fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis. Steroids  2015,101,56-63","journal-title":"Steroids"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/jid.2010.432","volume":"131","author":"Lindroos J.","year":"2011","unstructured":"Lindroos J.; Svensson L.; Norsgaard H.; Il-23-mediated epidermal hyperplasia is dependent on il-6. J Invest Dermatol  2011,131(5),1110-1118","journal-title":"J Invest Dermatol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1084\/jem.20160258","volume":"213","author":"Cheung K.L.","year":"2016","unstructured":"Cheung K.L.; Jarrett R.; Subramaniam S.; Psoriatic t cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by cd1a. J Exp Med  2016,213(11),2399-2412","journal-title":"J Exp Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jid.2022.01.014","volume":"142","author":"van de Kerkhof P.C.M.","year":"2022","unstructured":"van de Kerkhof P.C.M.; From empirical to pathogenesis-based treatments for psoriasis. J Invest Dermatol  2022,142(7),1778-1785","journal-title":"J Invest Dermatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/B978-0-323-85542-6.00020-2","author":"Nema N.K.","year":"2022","unstructured":"Nema N.K.; Chaudhary S.K.; Kar A.; Chapter 7 - Bioactive leads for skin aging\u2014current scenario and future perspectives. In: Mukherjee SE, Ed  2022,185-222","journal-title":"In: Mukherjee SE, Ed"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2174\/0115672018270783231002115728","volume":"21","author":"Ahuja A.","year":"2024","unstructured":"Ahuja A.; Bajpai M.; Nanoformulations insights: A novel paradigm for antifungal therapies and future perspectives. Curr Drug Deliv  2024,21(9),1241-1272","journal-title":"Curr Drug Deliv"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"103430","DOI":"10.1016\/j.jddst.2022.103430","volume":"74","author":"Yadav R.","year":"2022","unstructured":"Yadav R.; Pradhan M.; Yadav K.; Mahalvar A.; Yadav H.; Present scenarios and future prospects of herbal nanomedicine for antifungal therapy. J Drug Deliv Sci Technol  2022,74,103430","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrd3794","volume":"11","author":"Miossec P.","year":"2012","unstructured":"Miossec P.; Kolls J.K.; Targeting il-17 and th17 cells in chronic inflammation. Nat Rev Drug Discov  2012,11(10),763-776","journal-title":"Nat Rev Drug Discov"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"100151","DOI":"10.1016\/j.medidd.2023.100151","volume":"17","author":"Yadav H.","year":"2023","unstructured":"Yadav H.; Mahalvar A.; Pradhan M.; Yadav K.; Kumar Sahu K.; Yadav R.; Exploring the potential of phytochemicals and nanomaterial: A boon to antimicrobial treatment. Med Drug Discov  2023,17(6),100151","journal-title":"Med Drug Discov"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","volume":"13","author":"Zhou X.","year":"2022","unstructured":"Zhou X.; Chen Y.; Cui L.; Shi Y.; Guo C.; Advances in the pathogenesis of psoriasis: From keratinocyte perspective. Cell Death Dis  2022,13(1),81","journal-title":"Cell Death Dis"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1365-2230.2009.03410.x","volume":"34","author":"Rashmi R.","year":"2009","unstructured":"Rashmi R.; Rao K.S.J.; Basavaraj K.H.; A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol  2009,34(6),658-663","journal-title":"Clin Exp Dermatol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"102688","DOI":"10.1016\/j.jddst.2021.102688","volume":"65","author":"Yadav K.","year":"2021","unstructured":"Yadav K.; Singh D.; Singh M.R.; Nanovesicles delivery approach for targeting steroid mediated mechanism of antipsoriatic therapeutics. J Drug Deliv Sci Technol  2021,65,102688","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/B978-0-12-824390-9.00017-7","author":"Yadav K.","year":"2022","unstructured":"Yadav K.; Pradhan M.; Singh D.; Singh M.R.; Targeting autoimmune disorders through metal nanoformulation in overcoming the fences of conventional treatment approaches. In: Rezaei N, Ed. Transl Autoimmun  2022,361-393","journal-title":"Transl Autoimmun"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jaad.2013.12.036","volume":"71","author":"Lynde C.W.","year":"2014","unstructured":"Lynde C.W.; Poulin Y.; Vender R.; Bourcier M.; Khalil S.; Interleukin 17a: Toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol  2014,71(1),141-150","journal-title":"J Am Acad Dermatol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"E3422","DOI":"10.1073\/pnas.1400513111","volume":"111","author":"Ha H.L.","year":"2014","unstructured":"Ha H.L.; Wang H.; Pisitkun P.; Il-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms. Proc Natl Acad Sci USA  2014,111(33),E3422-E3431","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"102282","DOI":"10.1016\/j.jddst.2020.102282","volume":"61","author":"Pradhan M.","year":"2021","unstructured":"Pradhan M.; Yadav K.; Singh D.; Singh M.R.; Topical delivery of fluocinolone acetonide integrated nlcs and salicylic acid enriched gel: A potential and synergistic approach in the management of psoriasis. J Drug Deliv Sci Technol  2021,61,102282","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40204-021-00154-7","volume":"10","author":"Yadav K.","year":"2021","unstructured":"Yadav K.; Soni A.; Singh D.; Singh M.R.; Polymers in topical delivery of anti-psoriatic medications and other topical agents in overcoming the barriers of conventional treatment strategies. Prog Biomater  2021,10(1),1-17","journal-title":"Prog Biomater"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.2217\/nnm.13.202","volume":"9","author":"Marepally S.","year":"2014","unstructured":"Marepally S.; Boakye C.H.A.; Patel A.R.; Topical administration of dual sirnas using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine (Lond)  2014,9(14),2157-2174","journal-title":"Nanomedicine (Lond)"},{"key":"ref=47","first-page":"278","volume":"63","author":"Kim W.B.","year":"2017","unstructured":"Kim W.B.; Jerome D.; Yeung J.; Diagnosis and management of psoriasis. Can Fam Physician  2017,63(4),278-285","journal-title":"Can Fam Physician"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2310\/7750.2012.11124","volume":"17","author":"Wong T.","year":"2013","unstructured":"Wong T.; Hsu L.; Liao W.; Phototherapy in psoriasis: A review of mechanisms of action. J Cutan Med Surg  2013,17(1),6-12","journal-title":"J Cutan Med Surg"},{"key":"ref=49","first-page":"115","author":"Thakur A","year":"2024","unstructured":"Thakur A; Nagori K; Rao A; Rai N; Use of deep learning approaches for the prediction of diseases from medical images  2024,115-38"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"392","DOI":"10.2340\/00015555-1086","volume":"91","author":"Nylander K.","year":"2011","unstructured":"Nylander K.; Gu X.; Nylander E.; Coates P.J.; Effect of narrow-band ultraviolet b phototherapy on p63 and microrna (mir-21 and mir-125b) expression in psoriatic epidermis. Acta Derm Venereol  2011,91(4),392-397","journal-title":"Acta Derm Venereol"},{"key":"ref=51","first-page":"626","volume":"87","author":"Weigle N.","year":"2013","unstructured":"Weigle N.; McBane S.; Psoriasis. Am Fam Physician  2013,87(9),626-633","journal-title":"Am Fam Physician"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2174\/1567201817666200722141807","volume":"17","author":"Chavoshy F.","year":"2020","unstructured":"Chavoshy F.; Zadeh B.S.M.; Tamaddon A.M.; Anbardar M.H.; Delivery and anti-psoriatic effect of silibinin-loaded polymeric micelles: An experimental study in the psoriatic skin model. Curr Drug Deliv  2020,17(9),787-798","journal-title":"Curr Drug Deliv"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"103437","DOI":"10.1016\/j.jddst.2022.103437","volume":"73","author":"Yadav K.","year":"2022","unstructured":"Yadav K.; Singh D.; Singh M.R.; Dermal nanomedicine: Uncovering the ability of nucleic acid to alleviate autoimmune and other related skin disorders. J Drug Deliv Sci Technol  2022,73,103437","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3109\/21691401.2014.955105","volume":"44","author":"Pradhan M.","year":"2016","unstructured":"Pradhan M.; Singh D.; Singh M.R.; Influence of selected variables on fabrication of triamcinolone acetonide loaded solid lipid nanoparticles for topical treatment of dermal disorders. Artif Cells Nanomed Biotechnol  2016,44(1),392-400","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018020856","volume":"35","author":"Pradhan M.","year":"2018","unstructured":"Pradhan M.; Srivastava S.; Singh D.; Saraf S.; Saraf S.; Singh M.R.; Perspectives of lipid-based drug carrier systems for transdermal delivery. Crit Rev Ther Drug Carrier Syst  2018,35(4),331-367","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.biopha.2018.07.156","volume":"107","author":"Pradhan M.","year":"2018","unstructured":"Pradhan M.; Alexander A.; Singh M.R.; Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed Pharmacother  2018,107,447-463","journal-title":"Biomed Pharmacother"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-023-01399-3","volume":"8","author":"Qiu S.","year":"2023","unstructured":"Qiu S.; Cai Y.; Yao H.; Small molecule metabolites: Discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther  2023,8(1),132","journal-title":"Signal Transduct Target Ther"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"108254","DOI":"10.1016\/j.compbiolchem.2024.108254","volume":"113","author":"Abdelaziz E.H.","year":"2024","unstructured":"Abdelaziz E.H.; Ismail R.; Mabrouk M.S.; Amin E.; Multi-omics data integration and analysis pipeline for precision medicine: Systematic review. Comput Biol Chem  2024,113,108254","journal-title":"Comput Biol Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biopsych.2020.02.015","volume":"88","author":"Feczko E.","year":"2020","unstructured":"Feczko E.; Fair D.A.; Methods and challenges for assessing heterogeneity. Biol Psychiatry  2020,88(1),9-17","journal-title":"Biol Psychiatry"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/biom12091238","volume":"12","author":"Suravajhala P.","year":"2022","unstructured":"Suravajhala P.; Goltsov A.; Three grand challenges in high throughput omics technologies. Biomolecules  2022,12(9),1238","journal-title":"Biomolecules"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.3390\/ijms23095213","volume":"23","author":"Di Minno A.","year":"2022","unstructured":"Di Minno A.; Gelzo M.; Caterino M.; Costanzo M.; Ruoppolo M.; Castaldo G.; Challenges in metabolomics-based tests, biomarkers revealed by metabolomic analysis, and the promise of the application of metabolomics in precision medicine. Int J Mol Sci  2022,23(9),5213","journal-title":"Int J Mol Sci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.chembiol.2013.12.010","volume":"21","author":"Cummings R.D.","year":"2014","unstructured":"Cummings R.D.; Pierce J.M.; The challenge and promise of glycomics. Chem Biol  2014,21(1),1-15","journal-title":"Chem Biol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"174254","DOI":"10.1016\/j.ejphar.2021.174254","volume":"907","author":"Yadav K.","year":"2021","unstructured":"Yadav K.; Singh D.; Singh M.R.; Novel archetype in psoriasis management bridging molecular dynamics in exploring novel therapies. Eur J Pharmacol  2021,907,174254","journal-title":"Eur J Pharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"110022","DOI":"10.1016\/j.abb.2024.110022","volume":"756","author":"Tiwari P.","year":"2024","unstructured":"Tiwari P.; Yadav K.; Shukla R.P.; Extracellular vesicles-powered immunotherapy: Unleashing the potential for safer and more effective cancer treatment. Arch Biochem Biophys  2024,756,110022","journal-title":"Arch Biochem Biophys"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"966","DOI":"10.5958\/0974-360X.2021.00172.4","volume":"14","author":"Yadav K.","year":"2021","unstructured":"Yadav K.; Singh D.; Singh M.R.; Development and characterization of corticosteroid loaded lipid carrier system for psoriasis. RESEARCH JOURNAL OF PHARMACY AND TECHNOLOGY  2021,14(2),966-970","journal-title":"RESEARCH JOURNAL OF PHARMACY AND TECHNOLOGY"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"110331","DOI":"10.1016\/j.intimp.2023.110331","volume":"120","author":"Nikam R.V.","year":"2023","unstructured":"Nikam R.V.; Gowtham M.; More P.S.; Shinde A.S.; Current and emerging prospects in the psoriatic treatment. Int Immunopharmacol  2023,120,110331","journal-title":"Int Immunopharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.disamonth.2018.06.001","volume":"65","author":"Schadler E.D.","year":"2019","unstructured":"Schadler E.D.; Ortel B.; Mehlis S.L.; Biologics for the primary care physician: Review and treatment of psoriasis. Dis Mon  2019,65(3),51-90","journal-title":"Dis Mon"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-16-8117-2_1","author":"Singh M.R.","year":"2022","unstructured":"Singh M.R.; Yadav K.; Chaurasiya N.D.; Singh D.; Immune system and mechanism of immunomodulation. In: Sangwan NS, Farag MA, Modolo LV, Eds. Plants Phytomolecules Immunomodulation Recent Trends Adv  2022,1-31","journal-title":"Plants Phytomolecules Immunomodulation Recent Trends Adv"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/978-981-97-3925-7_1","author":"Yadav K.","year":"2024","unstructured":"Yadav K.; Ajazuddin A.; Anisamide-Anchored Lyotropic Nano-Liquid Crystalline Particles with AIE Effect: A Smart Optical Beacon for Tumor Imaging and Therapy. ACS Applied Materials and Interfaces  2024,10-15","journal-title":"ACS Applied Materials and Interfaces"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/21691401.2014.955106","volume":"44","author":"Singh D.","year":"2016","unstructured":"Singh D.; Singh S.; Sahu J.; Srivastava S.; Singh M.R.; Ceramic nanoparticles: Recompense, cellular uptake and toxicity concerns. Artif Cells Nanomed Biotechnol  2016,44(1),401-409","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.5958\/0974-360X.2018.00251.2","volume":"11","author":"Dewangan D.","year":"2018","unstructured":"Dewangan D.; Ajazuddin P.; Agrawal P.; Formulation and evaluation of oral reconstitutable azithromycin suspension for the treatment of bacterial infection. Research Journal of Pharmacy and Technology  2018,11(4),1351-1354","journal-title":"Research Journal of Pharmacy and Technology"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/ddg.13050","volume":"14","author":"Volc S.","year":"2016","unstructured":"Volc S.; Ghoreschi K.; Pathophysiologische grundlagen der systemtherapien bei psoriasis, jddg - j. Ger Soc Dermatology  2016,14,557-573","journal-title":"Ger Soc Dermatology"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/11538950-000000000-00000","volume":"12","author":"Kurzeja M.","year":"2011","unstructured":"Kurzeja M.; Rudnicka L.; Olszewska M.; New interleukin-23 pathway inhibitors in dermatology: Ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol  2011,12(2),113-125","journal-title":"Am J Clin Dermatol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.2147\/CCID.S426972","volume":"16","author":"Travaglini M.","year":"2023","unstructured":"Travaglini M.; Maul J.T.; Kors C.; Effectiveness of biologics, patient-reported outcomes, and clinical photography in a subset of patients with moderate-to-severe psoriasis: Week 12 results from the psoriasis study of health outcomes (psoho). Clin Cosmet Investig Dermatol  2023,16,2971-2983","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1185523","DOI":"10.3389\/fmed.2023.1185523","volume":"10","author":"Piaserico S.","year":"2023","unstructured":"Piaserico S.; Riedl E.; Pavlovsky L.; Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: Week 12 results from the observational psoriasis study of health outcomes (psoho). Front Med (Lausanne)  2023,10,1185523","journal-title":"Front Med (Lausanne)"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"adv00712","DOI":"10.2340\/actadv.v102.206","volume":"102","author":"Van Muijen M.E.","year":"2022","unstructured":"Van Muijen M.E.; Thomas S.E.; Groenewoud H.M.M.; Direct comparison of real-world effectiveness of biologics for psoriasis using absolute and relative psoriasis area and severity index scores in a prospective multicentre cohort. Acta Derm Venereol  2022,102,adv00712","journal-title":"Acta Derm Venereol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"Armstrong A.W.","year":"2020","unstructured":"Armstrong A.W.; Puig L.; Joshi A.; Comparison of biologics and oral treatments for plaque psoriasis. JAMA Dermatol  2020,156(3),258-269","journal-title":"JAMA Dermatol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/09546634.2019.1688756","volume":"32","author":"Sutaria N.","year":"2021","unstructured":"Sutaria N.; Au S.C.; Failure rates and survival times of systemic and biologic therapies in treating psoriasis: A retrospective study. J Dermatolog Treat  2021,32(6),617-620","journal-title":"J Dermatolog Treat"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.jidsymp.5650029","volume":"12","author":"Gottlieb A.B.","year":"2007","unstructured":"Gottlieb A.B.; Tumor necrosis factor blockade: Mechanism of action. J Investig Dermatol Symp Proc  2007,12(1),1-4","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.4049\/jimmunol.1001538","volume":"185","author":"Tonel G.","year":"2010","unstructured":"Tonel G.; Conrad C.; Laggner U.; Cutting edge: A critical functional role for il-23 in psoriasis. J Immunol  2010,185(10),5688-5691","journal-title":"J Immunol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1201\/9780429328275-14","author":"Minz S.","year":"2020","unstructured":"Minz S.; Rawat Singh M.; Singh D.; Parihar A.; Pradhan M.; Biotechnology-based prodrug approach for cell-specific targeting: its theoretical basis and application. Rec Adv Prodr  2020,317-332","journal-title":"Rec Adv Prodr"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"111919","DOI":"10.1016\/j.biopha.2021.111919","volume":"141","author":"Agrawal M.","year":"2021","unstructured":"Agrawal M.; Saraf S.; Pradhan M.; Design and optimization of curcumin loaded nano lipid carrier system using box-behnken design. Biomed Pharmacother  2021,141,111919","journal-title":"Biomed Pharmacother"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"100107","DOI":"10.1016\/j.onano.2022.100107","volume":"08","author":"Yadav K","year":"2022","unstructured":"Yadav K; Singh D; Singh MR; Pradhan M; Nano-constructs targeting the primary cellular energy source of cancer cells for modulating tumor progression OpenNano  2022,08(2022),100107","journal-title":"OpenNano"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"68421","DOI":"10.5772\/intechopen.68421","author":"Meephansan J","year":"2017","unstructured":"Meephansan J; Subpayasarn U.; Pathogenic Role of Cytokines and Effect of Their Inhibition in Psoriasis. An Interdisciplinary Approach to Psoriasis  2017,68421","journal-title":"An Interdisciplinary Approach to Psoriasis"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.intimp.2015.07.036","volume":"28","author":"Liu Y.","year":"2015","unstructured":"Liu Y.; Yang G.; Zhang J.; Anti-tnf-\u03b1 monoclonal antibody reverses psoriasis through dual inhibition of inflammation and angiogenesis. Int Immunopharmacol  2015,28(1),731-743","journal-title":"Int Immunopharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/bjd.19393","volume":"184","author":"Gordon K.B.","year":"2021","unstructured":"Gordon K.B.; Warren R.B.; Gottlieb A.B.; Long\u2010term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3\u2010year results from two randomized phase iii trials (cimpasi\u20101 and cimpasi\u20102). Br J Dermatol  2021,184(4),652-662","journal-title":"Br J Dermatol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","volume":"11","author":"Atiqi S.","year":"2020","unstructured":"Atiqi S.; Hooijberg F.; Loeff F.C.; Rispens T.; Wolbink G.J.; Immunogenicity of tnf-inhibitors. Front Immunol  2020,11,312","journal-title":"Front Immunol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13555-018-0230-9","volume":"8","author":"Carrascosa J.M.","year":"2018","unstructured":"Carrascosa J.M.; Jacobs I.; Petersel D.; Strohal R.; Biosimilar drugs for psoriasis: Principles, present, and near future. Dermatol Ther (Heidelb)  2018,8(2),173-194","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/TCRM.S5599","volume":"6","author":"Lebwohl M.","year":"2010","unstructured":"Lebwohl M.; Emer J.; Koutruba N.; Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manag  2010,6,123-141","journal-title":"Ther Clin Risk Manag"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/ijms19020530","volume":"19","author":"Boutet M.A.","year":"2018","unstructured":"Boutet M.A.; Nerviani A.; Gallo Afflitto G.; Pitzalis C.; Role of the il-23\/il-17 axis in psoriasis and psoriatic arthritis: The clinical importance of its divergence in skin and joints. Int J Mol Sci  2018,19(2),530","journal-title":"Int J Mol Sci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","volume":"9","author":"Sch\u00f6n M.P.","year":"2018","unstructured":"Sch\u00f6n M.P.; Erpenbeck L.; The interleukin-23\/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol  2018,9,1323","journal-title":"Front Immunol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"ii20","DOI":"10.1093\/ecco-jcc\/jjac023","volume":"16","author":"Valenti M.","year":"2022","unstructured":"Valenti M.; Narcisi A.; Pavia G.; Gargiulo L.; Costanzo A.; What can ibd specialists learn from il-23 trials in dermatology? J Crohn\u2019s Colitis  2022,16(Suppl. 2),ii20-ii29","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2147\/CCID.S364640","volume":"15","author":"Ruggiero A.","year":"2022","unstructured":"Ruggiero A.; Picone V.; Martora F.; Fabbrocini G.; Megna M.; Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: A review of the real-world evidence. Clin Cosmet Investig Dermatol  2022,15,1649-1658","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40265-017-0794-1","volume":"77","author":"Torres T.","year":"2017","unstructured":"Torres T.; Selective interleukin-23 p19 inhibition: Another game changer in psoriasis? focus on risankizumab. Drugs  2017,77(14),1493-1503","journal-title":"Drugs"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1039\/D0BM01033B","volume":"9","author":"Shukla R.P.","year":"2021","unstructured":"Shukla R.P.; Urandur S.; Banala V.T.; Development of putrescine anchored nano-crystalsomes bearing doxorubicin and oleanolic acid: Deciphering their role in inhibiting metastatic breast cancer. Biomater Sci  2021,9(5),1779-1794","journal-title":"Biomater Sci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s12026-022-09356-y","volume":"71","author":"Ruggiero A.","year":"2023","unstructured":"Ruggiero A.; Megna M.; Fabbrocini G.; Ocampo-Garza S.S.; Anti-il23 biologic therapies in the treatment of psoriasis: Real-world experience versus clinical trials data. Immunol Res  2023,71(3),328-355","journal-title":"Immunol Res"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/0115672050306008240321034006","volume":"21","author":"Nagori K.","year":"2024","unstructured":"Nagori K.; Pradhan M.; Sharma M.; Ajazuddin H.R.; Badwaik H.R.; Nakhate K.T.; Current progress on central cholinergic receptors as therapeutic targets for alzheimer\u2019s disease. Curr Alzheimer Res  2024,21(1),50-68","journal-title":"Curr Alzheimer Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"702776","DOI":"10.3389\/fmed.2021.702776","volume":"8","author":"Ghazawi F.M.","year":"2021","unstructured":"Ghazawi F.M.; Mahmood F.; Kircik L.; A review of the efficacy and safety for biologic agents targeting il-23 in treating psoriasis with the focus on tildrakizumab. Front Med (Lausanne)  2021,8,702776","journal-title":"Front Med (Lausanne)"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/jcm12041662","volume":"12","author":"Avallone G.","year":"2023","unstructured":"Avallone G.; Maronese C.A.; Murgia G.; Interleukin-17 vs. interleukin-23 inhibitors in pustular and erythrodermic psoriasis: A retrospective, multicentre cohort study. J Clin Med  2023,12(4),1662","journal-title":"J Clin Med"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3109\/09546634.2015.1115816","volume":"27","author":"Jinna S.","year":"2016","unstructured":"Jinna S.; Strober B.; Anti-interleukin-17 treatment of psoriasis. J Dermatolog Treat  2016,27(4),311-315","journal-title":"J Dermatolog Treat"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","volume":"9","author":"Brembilla N.C.","year":"2018","unstructured":"Brembilla N.C.; Senra L.; Boehncke W.H.; The il-17 family of cytokines in psoriasis: Il-17a and beyond. Front Immunol  2018,9,1682","journal-title":"Front Immunol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13555-018-0220-y","volume":"8","author":"Spindeldreher S.","year":"2018","unstructured":"Spindeldreher S.; Maill\u00e8re B.; Correia E.; Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab. Dermatol Ther (Heidelb)  2018,8(1),57-68","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5114\/ada.2016.61599","volume":"4","author":"Wasilewska A.","year":"2016","unstructured":"Wasilewska A.; Winiarska M.; Olszewska M.; Rudnicka L.; Interleukin-17 inhibitors. a new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol  2016,4(4),247-252","journal-title":"Postepy Dermatol Alergol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"e13403","DOI":"10.1111\/dth.13403","volume":"33","author":"Facheris P.","year":"2020","unstructured":"Facheris P.; Valenti M.; Pavia G.; Brodalumab: A new way to inhibit il \u201017 in psoriasis. Dermatol Ther  2020,33(3),e13403","journal-title":"Dermatol Ther"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","volume":"81","author":"Nakagawa H.","year":"2016","unstructured":"Nakagawa H.; Niiro H.; Ootaki K.; Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase ii randomized controlled study. J Dermatol Sci  2016,81(1),44-52","journal-title":"J Dermatol Sci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","volume":"54","author":"Conrad C.","year":"2018","unstructured":"Conrad C.; Gilliet M.; Psoriasis: From pathogenesis to targeted therapies. Clin Rev Allergy Immunol  2018,54(1),102-113","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/protein\/gzv034","volume":"28","author":"Stenderup K.","year":"2015","unstructured":"Stenderup K.; Rosada C.; Shanebeck K.; Az17: A new bispecific drug targeting il-6 and il-23 with potential clinical use\u2014improves psoriasis in a human xenograft transplantation model. Protein Eng Des Sel  2015,28(10),467-480","journal-title":"Protein Eng Des Sel"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/jdv.17071","volume":"35","author":"Kaul M.","year":"2021","unstructured":"Kaul M.; Jarvis P.; Rozenberg I.; First\u2010in\u2010human study demonstrating the safety and clinical efficacy of novel anti\u2010il\u201017a monoclonal antibody cjm112 in moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol  2021,35(5),1143-1151","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1080\/21645515.2017.1356498","volume":"13","author":"Jeon C.","year":"2017","unstructured":"Jeon C.; Sekhon S.; Yan D.; Afifi L.; Nakamura M.; Bhutani T.; Monoclonal antibodies inhibiting il-12, -23, and -17 for the treatment of psoriasis. Hum Vaccin Immunother  2017,13(10),2247-2259","journal-title":"Hum Vaccin Immunother"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.clim.2007.01.006","volume":"123","author":"Chong B.F.","year":"2007","unstructured":"Chong B.F.; Wong H.K.; Immunobiologics in the treatment of psoriasis. Clin Immunol  2007,123(2),129-138","journal-title":"Clin Immunol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"113316","DOI":"10.1016\/j.colsurfb.2023.113316","volume":"226","author":"Marwaha D.","year":"2023","unstructured":"Marwaha D.; Gautam S.; Singh N.; Synergistic delivery of imatinib through multifunctional nano-crystalline capsules, in response to redox environment for improved breast cancer therapy. Colloids Surf B Biointerfaces  2023,226,113316","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","volume":"11","author":"Puig L.","year":"2021","unstructured":"Puig L.; Bakulev A.L.; Kokhan M.M.; Efficacy and safety of netakimab, a novel anti-il-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. results of a 54-week randomized double-blind placebo-controlled planeta clinical trial. Dermatol Ther (Heidelb)  2021,11(4),1319-1332","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"Boehncke W.H.","year":"2015","unstructured":"Boehncke W.H.; Sch\u00f6n M.P.; Psoriasis. Lancet  2015,386(9997),983-994","journal-title":"Lancet"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clindermatol.2007.10.027","volume":"26","author":"Sch\u00f6n M.P.","year":"2008","unstructured":"Sch\u00f6n M.P.; Efalizumab in the treatment of psoriasis: Mode of action, clinical indications, efficacy, and safety. Clin Dermatol  2008,26(5),509-514","journal-title":"Clin Dermatol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/cpt.688","volume":"102","author":"Turbeville J.G.","year":"2017","unstructured":"Turbeville J.G.; Patel N.U.; Cardwell L.A.; Oussedik E.; Feldman S.R.; Recent advances in small molecule and biological therapeutic approaches in the treatment of psoriasis. Clin Pharmacol Ther  2017,102(1),70-85","journal-title":"Clin Pharmacol Ther"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s41927-022-00287-7","volume":"6","author":"Sarabia S.","year":"2022","unstructured":"Sarabia S.; Ranjith B.; Koppikar S.; Wijeratne D.T.; Efficacy and safety of jak inhibitors in the treatment of psoriasis and psoriatic arthritis: A systematic review and meta-analysis. BMC Rheumatol  2022,6(1),71","journal-title":"BMC Rheumatol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","volume":"37","author":"Jiang Y.","year":"2023","unstructured":"Jiang Y.; Chen Y.; Yu Q.; Shi Y.; Biologic and small-molecule therapies for moderate-to-severe psoriasis: Focus on psoriasis comorbidities. BioDrugs  2023,37(1),35-55","journal-title":"BioDrugs"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/14712598.2022.2089020","volume":"22","author":"Megna M.","year":"2022","unstructured":"Megna M.; Potestio L.; Fabbrocini G.; Camela E.; Treating psoriasis in the elderly: Biologics and small molecules. Expert Opin Biol Ther  2022,22(12),1503-1520","journal-title":"Expert Opin Biol Ther"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","volume":"80","author":"Nogueira M.","year":"2020","unstructured":"Nogueira M.; Puig L.; Torres T.; Jak inhibitors for treatment of psoriasis: Focus on selective tyk2 inhibitors. Drugs  2020,80(4),341-352","journal-title":"Drugs"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1002\/jhet.2934","volume":"54","author":"Dewangan D.","year":"2017","unstructured":"Dewangan D.; Nakhate K.T.; Verma V.S.; Nagori K.; Tripathi D.K.; Synthesis, characterization, and screening for analgesic and anti\u2010inflammatory activities of schiff bases of 1,3,4\u2010oxadiazoles linked with quinazolin\u20104\u2010one. J Heterocycl Chem  2017,54(6),3187-3194","journal-title":"J Heterocycl Chem"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1124\/jpet.115.223784","volume":"354","author":"Fukuyama T.","year":"2015","unstructured":"Fukuyama T.; Ehling S.; Cook E.; B\u00e4umer W.; Topically administered janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J Pharmacol Exp Ther  2015,354(3),394-405","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","volume":"74","author":"Papp K.A.","year":"2016","unstructured":"Papp K.A.; Krueger J.G.; Feldman S.R.; Tofacitinib, an oral janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-iii studies and 1 open-label long-term extension study. J Am Acad Dermatol  2016,74(5),841-850","journal-title":"J Am Acad Dermatol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/1567201816666191120120551","volume":"17","author":"Ramanunny A.K.","year":"2020","unstructured":"Ramanunny A.K.; Wadhwa S.; Singh S.K.; Sharma D.S.; Khursheed R.; Awasthi A.; Treatment strategies against psoriasis: Principle, perspectives and practices. Curr Drug Deliv  2020,17(1),52-73","journal-title":"Curr Drug Deliv"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"Schwartz D.M.","year":"2018","unstructured":"Schwartz D.M.; Kanno Y.; Villarino A.; Ward M.; Gadina M.; O\u2019Shea J.J.; Erratum: Jak inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov  2018,17(1),78","journal-title":"Nat Rev Drug Discov"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.3390\/ijms19123973","volume":"19","author":"Jin W.","year":"2018","unstructured":"Jin W.; Huang W.; Chen L.; Topical application of jak1\/jak2 inhibitor momelotinib exhibits significant anti-inflammatory responses in dncb-induced atopic dermatitis model mice. Int J Mol Sci  2018,19(12),3973","journal-title":"Int J Mol Sci"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"10","DOI":"10.52228\/JRUB.2018-31-1-2","volume":"31","author":"Yadav K.","year":"2019","unstructured":"Yadav K.; Pawar J.; Singh D.; Singh M.R.; Promising phytoactives candidates for efficacious treatment of psoriasis and other skin disorders. J Ravishankar Univ  2019,31(1),10-22","journal-title":"J Ravishankar Univ"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2174\/9789815049787122010007","author":"Parashar A.","year":"2022","unstructured":"Parashar A.; Patel P.; Kaurav M.; Nanomaterials as diagnostic tools and drug carriers. Nanoparticles Nanocarriers-Based Pharmaceutical Formula  2022,126-156","journal-title":"Nanoparticles Nanocarriers-Based Pharmaceutical Formula"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/B978-0-323-91942-5.00003-3","author":"Yadav K.","year":"2023","unstructured":"Yadav K.; Singh D.; Singh M.R.; Chauhan N.S.; Minz S.; Pradhan M.; Chapter 18 - Nanobiomaterials as novel modules in the delivery of artemisinin and its derivatives for effective management of malaria. In: Chauhan BDM, Ed  2023,447-466","journal-title":"In: Chauhan BDM, Ed"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/1744666X.2022.2039121","volume":"18","author":"Funk P.J.","year":"2022","unstructured":"Funk P.J.; Perche P.O.; Singh R.; Kelly K.A.; Feldman S.R.; Comparing available jak inhibitors for treating patients with psoriasis. Expert Rev Clin Immunol  2022,18(3),281-294","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.4049\/jimmunol.0900521","volume":"183","author":"Wang H.","year":"2009","unstructured":"Wang H.; Syrovets T.; Kess D.; Targeting nf-kappa b with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. J Immunol  2009,183(7),4755-4763","journal-title":"J Immunol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1021\/acs.molpharmaceut.2c00673","volume":"20","author":"Gautam S.","year":"2023","unstructured":"Gautam S.; Marwaha D.; Singh N.; Self-assembled redox-sensitive polymeric nanostructures facilitate the intracellular delivery of paclitaxel for improved breast cancer therapy. Mol Pharm  2023,20(4),1914-1932","journal-title":"Mol Pharm"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/biom9090410","volume":"9","author":"Kabir E.R.","year":"2019","unstructured":"Kabir E.R.; Moreino S.S.; Sharif Siam M.K.; The breakthrough of biosimilars: A twist in the narrative of biological therapy. Biomolecules  2019,9(9),410","journal-title":"Biomolecules"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.2147\/DDDT.S200147","volume":"13","author":"Subedi S.","year":"2019","unstructured":"Subedi S.; Gong Y.; Chen Y.; Shi Y.; Infliximab and biosimilar infliximab in psoriasis: Efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther  2019,13,2491-2502","journal-title":"Drug Des Devel Ther"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","volume":"157","author":"Loft N.","year":"2021","unstructured":"Loft N.; Egeberg A.; Rasmussen M.K.; Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis. JAMA Dermatol  2021,157(6),676-683","journal-title":"JAMA Dermatol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s40265-021-01610-1","volume":"81","author":"Mysler E.","year":"2021","unstructured":"Mysler E.; Azevedo V.F.; Danese S.; Biosimilar-to-biosimilar switching: What is the rationale and current experience? Drugs  2021,81(16),1859-1879","journal-title":"Drugs"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"161","DOI":"10.12998\/wjcc.v6.i8.161","volume":"6","author":"Kaida-Yip F.","year":"2018","unstructured":"Kaida-Yip F.; Deshpande K.; Saran T.; Vyas D.; Biosimilars: Review of current applications, obstacles, and their future in medicine. World J Clin Cases  2018,6(8),161-166","journal-title":"World J Clin Cases"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.xphs.2021.02.003","volume":"110","author":"Coghlan J.","year":"2021","unstructured":"Coghlan J.; He H.; Schwendeman A.S.; Overview of humira biosimilars: Current european landscape and future implications. J Pharm Sci  2021,110(4),1572-1582","journal-title":"J Pharm Sci"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"Kvien T.K.","year":"2022","unstructured":"Kvien T.K.; Patel K.; Strand V.; The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum  2022,52,151939","journal-title":"Semin Arthritis Rheum"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"20420986221125006","DOI":"10.1177\/20420986221125006","volume":"13","author":"Lucas S.","year":"2022","unstructured":"Lucas S.; Ailani J.; Smith T.R.; Abdrabboh A.; Xue F.; Navetta M.S.; Pharmacovigilance: Reporting requirements throughout a product\u2019s lifecycle. Ther Adv Drug Saf  2022,13,20420986221125006","journal-title":"Ther Adv Drug Saf"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","volume":"78","author":"Cohen H.P.","year":"2018","unstructured":"Cohen H.P.; Blauvelt A.; Rifkin R.M.; Danese S.; Gokhale S.B.; Woollett G.; Switching reference medicines to biosimilars: A systematic literature review of clinical outcomes. Drugs  2018,78(4),463-478","journal-title":"Drugs"},{"key":"ref=141","first-page":"612","volume":"16","author":"Barsell A.","year":"2017","unstructured":"Barsell A.; Rengifo-Pardo M.; Ehrlich A.; A survey assessment of us dermatologists\u2019 perception of biosimilars. J Drugs Dermatol  2017,16(6),612-615","journal-title":"J Drugs Dermatol"},{"key":"ref=142","first-page":"3","volume":"7","author":"Mulcahy A.W.","year":"2018","unstructured":"Mulcahy A.W.; Hlavka J.P.; Case S.R.; Biosimilar cost savings in the united states: Initial experience and future potential. Rand Health Q  2018,7(4),3","journal-title":"Rand Health Q"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"e65695","DOI":"10.1371\/journal.pone.0065695","volume":"8","author":"Thomas S.","year":"2013","unstructured":"Thomas S.; Sharma N.; Gonzalez R.; Repositioning of verrucosidin, a purported inhibitor of chaperone protein grp78, as an inhibitor of mitochondrial electron transport chain complex i. PLoS One  2013,8(6),e65695","journal-title":"PLoS One"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fonc.2019.00767","volume":"9","author":"Cao Y.","year":"2019","unstructured":"Cao Y.; Lu W.; Sun R.; Anti-cd19 chimeric antigen receptor t cells in combination with nivolumab are safe and effective against relapsed\/refractory b-cell non-hodgkin lymphoma. Front Oncol  2019,9,767","journal-title":"Front Oncol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"107086","DOI":"10.1016\/j.phrs.2024.107086","volume":"201","author":"Puccetti M.","year":"2024","unstructured":"Puccetti M.; Pariano M.; Schoubben A.; Giovagnoli S.; Ricci M.; Biologics, theranostics, and personalized medicine in drug delivery systems. Pharmacol Res  2024,201,107086","journal-title":"Pharmacol Res"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2174\/1871530320666200604162258","volume":"21","author":"Ramanunny A.K.","year":"2021","unstructured":"Ramanunny A.K.; Wadhwa S.; Thakur D.; Singh S.K.; Kumar R.; Treatment modalities of psoriasis: A focus on requisite for topical nanocarrier. Endocr Metab Immune Disord Drug Targets  2021,21(3),418-433","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","volume":"22","author":"Thatiparthi A.","year":"2021","unstructured":"Thatiparthi A.; Martin A.; Liu J.; Egeberg A.; Wu J.J.; Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: A review. Am J Clin Dermatol  2021,22(4),425-442","journal-title":"Am J Clin Dermatol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.fertnstert.2018.05.006","volume":"109","author":"Goetz L.H.","year":"2018","unstructured":"Goetz L.H.; Schork N.J.; Personalized medicine: Motivation, challenges, and progress. Fertil Steril  2018,109(6),952-963","journal-title":"Fertil Steril"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40264-021-01065-z","volume":"44","author":"Bissonnette R.","year":"2021","unstructured":"Bissonnette R.; Gottlieb A.B.; Langley R.G.; Signal detection and methodological limitations in a real-world registry: Learnings from the evaluation of long-term safety analyses in psolar. Drug Saf  2021,44(6),699-709","journal-title":"Drug Saf"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ph17010014","volume":"17","author":"Krzysztofik M.","year":"2023","unstructured":"Krzysztofik M.; Brzewski P.; Cuber P.; Risk of melanoma and non-melanoma skin cancer in patients with psoriasis and psoriatic arthritis treated with targeted therapies: A systematic review and meta-analysis. Pharmaceuticals (Basel)  2023,17(1),14","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1294416","DOI":"10.3389\/fimmu.2023.1294416","volume":"14","author":"Wu S.","year":"2023","unstructured":"Wu S.; Xu Y.; Yang L.; Guo L.; Jiang X.; Short-term risk and long-term incidence rate of infection and malignancy with il-17 and il-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Front Immunol  2023,14,1294416","journal-title":"Front Immunol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"e0296821","DOI":"10.1371\/journal.pone.0296821","volume":"19","author":"Bergmans B.","year":"2024","unstructured":"Bergmans B.; Jessurun N.; van Lint J.; Murk J.L.; van Puijenbroek E.; de Vries E.; Burden of non-serious infections during biological use for rheumatoid arthritis. PLoS One  2024,19(2),e0296821","journal-title":"PLoS One"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00296-022-05136-x","volume":"42","author":"Evangelatos G.","year":"2022","unstructured":"Evangelatos G.; Bamias G.; Kitas G.D.; Kollias G.; Sfikakis P.P.; The second decade of anti-tnf-a therapy in clinical practice: New lessons and future directions in the covid-19 era. Rheumatol Int  2022,42(9),1493-1511","journal-title":"Rheumatol Int"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/biomedicines11020318","volume":"11","author":"Tsiogka A.","year":"2023","unstructured":"Tsiogka A.; Gregoriou S.; Stratigos A.; The impact of treatment with il-17\/il-23 inhibitors on subclinical atherosclerosis in patients with plaque psoriasis and\/or psoriatic arthritis: A systematic review. Biomedicines  2023,11(2),318","journal-title":"Biomedicines"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/PTT.S328575","volume":"12","author":"Al-Janabi A.","year":"2022","unstructured":"Al-Janabi A.; Yiu Z.Z.N.; Biologics in psoriasis: Updated perspectives on long-term safety and risk management. Psoriasis (Auckl)  2022,12,1-14","journal-title":"Psoriasis (Auckl)"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013005268","volume":"30","author":"Raut A.S.","year":"2013","unstructured":"Raut A.S.; Prabhu R.H.; Patravale V.B.; Psoriasis clinical implications and treatment: A review. Crit Rev Ther Drug Carrier Syst  2013,30(3),183-216","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub4","volume":"2021","author":"Sbidian E.","year":"2021","unstructured":"Sbidian E.; Chaimani A.; Garcia-Doval I.; Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Libr  2021,2021(12),CD011535","journal-title":"Cochrane Libr"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s12035-020-01889-3","volume":"57","author":"Martins A.M.","year":"2020","unstructured":"Martins A.M.; Ascenso A.; Ribeiro H.M.; Marto J.; Current and future therapies for psoriasis with a focus on serotonergic drugs. Mol Neurobiol  2020,57(5),2391-2419","journal-title":"Mol Neurobiol"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/futurepharmacol3040053","volume":"3","author":"Nagori K.","year":"2023","unstructured":"Nagori K.; Nakhate K.T.; Yadav K.; Ajazuddin M.; Pradhan M.; Unlocking the therapeutic potential of medicinal plants for alzheimer\u2019s disease: Preclinical to clinical trial insights. Future Pharmacol  2023,3(4),877-907","journal-title":"Future Pharmacol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"Korman N.J.","year":"2020","unstructured":"Korman N.J.; Management of psoriasis as a systemic disease: What is the evidence? Br J Dermatol  2020,182(4),840-848","journal-title":"Br J Dermatol"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"5860","DOI":"10.2174\/0929867325666180522085716","volume":"25","author":"Poddighe D.","year":"2019","unstructured":"Poddighe D.; Romano M.; Gattinara M.; Gerloni V.; Biologics for the treatment of juvenile idiopathic arthritis. Curr Med Chem  2019,25(42),5860-5893","journal-title":"Curr Med Chem"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/jhet.3363","volume":"55","author":"Dewangan D.","year":"2018","unstructured":"Dewangan D.; Nakhate K.T.; Verma V.S.; Synthesis and molecular docking study of novel hybrids of 1,3,4\u2010oxadiazoles and quinoxaline as a potential analgesic and anti\u2010inflammatory agents. J Heterocycl Chem  2018,55(12),2901-2910","journal-title":"J Heterocycl Chem"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12969-021-00629-8","volume":"19","author":"Zaripova L.N.","year":"2021","unstructured":"Zaripova L.N.; Midgley A.; Christmas S.E.; Beresford M.W.; Baildam E.M.; Oldershaw R.A.; Juvenile idiopathic arthritis: From aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J  2021,19(1),135","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3109\/21691401.2014.883401","volume":"43","author":"Singh D.","year":"2015","unstructured":"Singh D.; Pradhan M.; Nag M.; Singh M.R.; Vesicular system: Versatile carrier for transdermal delivery of bioactives. Artif Cells Nanomed Biotechnol  2015,43(4),282-290","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/sj.jidsymp.5650037","volume":"12","author":"Tan J.K.","year":"2007","unstructured":"Tan J.K.; Aphale A.; Malaviya R.; Sun Y.; Gottlieb A.B.; Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc  2007,12(1),38-45","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"e0147979","DOI":"10.1371\/journal.pone.0147979","volume":"11","author":"Smith S.H.","year":"2016","unstructured":"Smith S.H.; Peredo C.E.; Takeda Y.; Development of a topical treatment for psoriasis targeting ror\u03b3: From bench to skin. PLoS One  2016,11(2),e0147979","journal-title":"PLoS One"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"247","DOI":"10.36849\/JDD.7399","volume":"22","author":"Kircik L.","year":"2023","unstructured":"Kircik L.; Bhatia N.; Lain E.; Jacobson A.; Breaking the frustrating cycle of topical steroids in psoriasis: A review of a novel vehicle for fixed-dose combination halobetasol propionate\/tazarotene. J Drugs Dermatol  2023,22(3),247-251","journal-title":"J Drugs Dermatol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"20406223211037846","DOI":"10.1177\/20406223211037846","volume":"12","author":"Iznardo H.","year":"2021","unstructured":"Iznardo H.; Puig L.; Dual inhibition of il-17a and il-17f in psoriatic disease. Ther Adv Chronic Dis  2021,12,20406223211037846","journal-title":"Ther Adv Chronic Dis"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/imm.13843","volume":"173","author":"Deng G.","year":"2024","unstructured":"Deng G.; Zhang Y.; Song J.; The role and therapeutic strategies for tissue\u2010resident memory t cells, central memory t cells, and effector memory t cells in psoriasis. Immunology  2024,173(3),470-480","journal-title":"Immunology"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40501-024-00326-9","volume":"11","author":"Rom\u00e3o J.","year":"2024","unstructured":"Rom\u00e3o J.; Melo A.; Andr\u00e9 R.; Novais F.; Machine learning as a tool to find new pharmacological targets in mood disorders: A systematic review. Curr Treat Options Psychiatry  2024,11(3),241-264","journal-title":"Curr Treat Options Psychiatry"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000536499","volume":"8","author":"Xing Y.","year":"2024","unstructured":"Xing Y.; Zhong S.; Aronson S.L.; Deep learning-based psoriasis assessment: Harnessing clinical trial imaging for accurate psoriasis area severity index prediction. Digit Biomark  2024,8(1),13-21","journal-title":"Digit Biomark"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"e44932","DOI":"10.2196\/44932","volume":"25","author":"Huang K.","year":"2023","unstructured":"Huang K.; Wu X.; Li Y.; Artificial intelligence\u2013based psoriasis severity assessment: Real-world study and application. J Med Internet Res  2023,25,e44932","journal-title":"J Med Internet Res"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/BTT.S252578","volume":"15","author":"Brownstone N.","year":"2021","unstructured":"Brownstone N.; Hong J.; Mosca M.; Biologic treatments of psoriasis: An update for the clinician. Biologics  2021,15,39-51","journal-title":"Biologics"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"1027347","DOI":"10.3389\/fmed.2022.1027347","volume":"9","author":"Felix P.A.O.","year":"2022","unstructured":"Felix P.A.O.; Sampaio A.L.; Silva B.L.; Viana A.L.P.; Early intervention in psoriasis: Where do we go from here? Front Med (Lausanne)  2022,9,1027347","journal-title":"Front Med (Lausanne)"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40012-023-00380-3","volume":"11","author":"Kasoju N.","year":"2023","unstructured":"Kasoju N.; Remya N.S.; Sasi R.; Digital health: Trends, opportunities and challenges in medical devices, pharma and bio-technology. CSI Transactions on ICT  2023,11(1),11-30","journal-title":"CSI Transactions on ICT"}],"container-title":["Recent Advances in Inflammation &amp; Allergy Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127722708331606250128063129","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/239212\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127722708331606250128063129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T04:10:29Z","timestamp":1773634229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/239212\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":175,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127722708331606250128063129","relation":{},"ISSN":["2772-2708"],"issn-type":[{"value":"2772-2708","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}